ArticleBMJ case reports2022
Long-term 14-year survival with primary hepatic angiosarcoma.
Article in BMJ case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary hepatic angiosarcomas (PHAs) are rare primary liver malignancies with poor outcomes due to their aggressive nature and the difficulty it presents in terms of diagnosis and management. However, early diagnosis and aggressive surgical resection combined with ongoing surveillance can confer prolonged survival in patients with PHA. Additionally, adjuvant radiotherapy may be of benefit in cases of involved surgical margins. Here we report the longest surviving patient with PHA in literature to date. The patient had an initial right hemihepatectomy 14 years ago and 10 years later had a segment III segmentectomy for recurrence on surveillance imaging. This was followed with adjuvant radiotherapy for involved margins. There has been no further recurrence noted on imaging to date, and the patient is continuing to thrive in the community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.